Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results Journal Article
| Authors: | Morris, M. J.; Molina, A.; Small, E. J.; de Bono, J. S.; Logothetis, C. J.; Fizazi, K.; De Souza, P.; Kantoff, P. W.; Higano, C. S.; Li, J. H.; Kheoh, T.; Larson, S. M.; Matheny, S. L.; Naini, V.; Burzykowski, T.; Griffin, T. W.; Scher, H. I.; Ryan, C. J. |
| Article Title: | Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results |
| Abstract: | Purpose Progression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC) trials has been inconsistently defined and poorly associated with overall survival (OS). A reproducible quantitative definition of radiographic PFS (rPFS) was tested for association with a coprimary end point of OS in a randomized trial of abiraterone in patients with mCRPC. Patients and Methods rPFS was defined as two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, two new confirmed lesions on any scan 12 weeks after random assignment, and/or progression in nodes or viscera on cross-sectional imaging, or death. rPFS was assessed by independent review at 15% of deaths and by investigator review at 15% and 40% of deaths. rPFS and OS association was evaluated by Spearman's correlation. Results A total of 1,088 patients were randomly assigned to abiraterone plus prednisone or prednisone alone. At first interim analysis, the hazard ratio (HR) by independent review was 0.43 (95% CI, 0.35 to 0.52; P < .001; abiraterone plus prednisone: median rPFS, not estimable; prednisone: median rPFS, 8.3 months). Similar HRs were obtained by investigator review at the first two interim analyses (HR, 0.49; 95% CI, 0.41 to 0.60; P < .001 and HR, 0.53; 95% CI, 0.45 to 0.62; P < .001, respectively), validating the imaging data assay used. Spearman's correlation coefficient between rPFS and OS was 0.72. Conclusion rPFS was highly consistent and highly associated with OS, providing initial prospective evidence on further developing rPFS as an intermediate end point in mCRPC trials. (C) 2015 by American Society of Clinical Oncology |
| Keywords: | prednisone; chemotherapy; abiraterone acetate; end-points; clinical-trials; men; phase-3 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 12 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-04-20 |
| Start Page: | 1356 |
| End Page: | 1363 |
| Language: | English |
| ACCESSION: | WOS:000356058800009 |
| DOI: | 10.1200/jco.2014.55.3875 |
| PROVIDER: | wos |
| PUBMED: | 25624432 |
| PMCID: | PMC4881370 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work